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doi:10.1Objective: The aim of this study was to compare the cost and effectiveness of a minimally invasive (MI) versus
traditional sternotomy (ST) approach for mitral valve surgery (MVS).
Methods: From January 1, 2003, to December 31, 2008, a total of 847 patients underwent isolated MVS at our
institution. Propensity matching on 22 clinical variables was carried out to generate a study cohort of 434 pa-
tients (217 matched pairs). Direct and indirect costs from the hospital perspective were retrospectively obtained
from our finance department. Total hospital costs were further stratified into 13 standardized institutional billing
categories. In addition, data on morbidity, mortality, discharge location, hospital readmissions within 1 year, and
freedom from reoperation were obtained.
Results: Compared with ST, MIMVS was associated with a $9054  $3302 lower mean total hospital cost
(P ¼ .006), driven largely by a reduction in direct (P ¼ .003) versus indirect costs (P ¼ .06). Among the 13
billing categories, MIMVS was associated with a significant reduction in costs of cardiac imaging
(P¼ .004), laboratory tests (P¼ .005), boarding and nursing (P¼ .001), and radiology (P¼ .002). More patients
in the ST group required intubation for more than 72 hours (P ¼ .019); however, there were no differences in
morbidity or long-term survival (P ¼ .334). A higher proportion of MI patients were discharged home with
no nursing services (P ¼ .018), and a higher proportion of ST patients required readmission within 1 year
(P ¼ .023). There were no differences in freedom from reoperation between groups (P ¼ .574).
Conclusions:With equivalent efficacy across a range of measures and lower costs compared with ST, MIMVS
represents a cost-saving strategy for MVS. (J Thorac Cardiovasc Surg 2011;142:1507-14)A
C
DDuring the past 10 years, there has been an increase in the
number of studies on outcomes of minimally invasivemitral
valve surgery (MIMVS).1-4 Since the first description of
MIMVS by Cohn and associates5 and Navia and Cosgrove6
in the mid-1990s, various minimally invasive (MI) ap-
proaches have been reported including the parasternal,
hemisternotomy, minithoracotomy, and totally endoscopic
approach.5-8 Despite the variation in surgical approaches,
the shared goal of MIMVS is to provide a safe and
effective option for mitral valve surgery (MVS) with the
clinical benefits associated with a minimal access approach.
Some of the reported benefits of MIMVS include de-
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The Journal of Thoracic and Carrespiratory function, reduced surgical trauma, and im-
proved cosmesis and patient satisfaction.9-11 In addition,
other reported benefits include decreased intensive care
unit and total hospital length of stay, faster physical
rehabilitation, and decreased overall hospital resource
use.5,12-14
These reported benefits have often been tempered by con-
cerns regarding the safety and durability of an MI approach,
the potential disadvantages of decreased surgical exposure,
and the potential for increased operative times. Although
there are currently no prospective, randomized trials com-
paring an MI to a sternotomy (ST) approach for MVS, sev-
eral single-institution studies have confirmed that many of
the proposed benefits of MIMVS can be achieved with no
detrimental effects on morbidity, mortality, or long-term
valve function.15-18
Although early studies have suggested lower hospital
costs associated with MIMVS,7,19,20 no studies in the past
decade have specifically performed a detailed economic
evaluation of this approach. In this analysis we assess the
cost-effectiveness of anMI versus an STapproach for MVS.
METHODS AND PATIENTS
Study Population
From January 1, 2003, to December 31, 2008, a total of 847 patients un-
derwent isolated MVS at our institution. After obtaining institutionaldiovascular Surgery c Volume 142, Number 6 1507
Abbreviations and Acronyms
MI ¼ minimally invasive
MIMVS ¼ minimally invasive mitral valve
surgery
MVS ¼ mitral valve surgery
ST ¼ sternotomy
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Dreview board approval, we retrospectively gathered data on patient
demographics, hospital costs, operative parameters, and both short- and
long-term morbidity and mortality using data from our hospital finance de-
partment, institutional medical records, and operative reports that comprise
our internal cardiac surgery registry, as well as data from the New York
State Cardiac Surgery Database.21
IsolatedMVSwas defined as anymitral valve repair or replacement per-
formed in the absence of a major concomitant procedure such as coronary
artery bypass grafting or other valve surgery. A total of 209 (24.7%) pa-
tients underwent minor concomitant procedures including atrial fibrillation
ablation (n ¼ 149, 17.6%) and atrial septal defect repair (n ¼ 60, 7.1%).
There were 316 mitral valve replacements (37.3%) and 531 mitral valve
repairs (62.7%). A traditional median ST approach was used in 348
(41.1%) patients and an MI approach was used in 499 (58.9%) patients.
Although MIMVS can be defined broadly as per Society of Thoracic Sur-
geons Database guidelines as any mitral valve repair or replacement per-
formed through an incision other than a full median sternotomy, in our
analysis MIMVS was isolated to either a minithoracotomy, which was
used in the majority of cases, or a hemisternotomy approach.22 Robotic mi-
tral valve surgery was not included in the analysis.Operative Technique
Among the MIMVS cases, 496 (99.4%) were performed through a right
minithoracotomy and 3 (0.6%) were performed through a hemisternotomy.
Our operative approach for MIMVS performed through a minithoracotomy
has been described previously.18 Of note, aortic cannulation was most com-
monly performed in a central fashion and venous drainage was most com-
monly achieved through a percutaneous femoral vein approach using single
multistage venous cannulation. Central aortic cannulation was performed
through the initial thoracotomy incision and a transthoracic aortic cross-
clamp (Chitwood) was passed through a stab wound in the right axilla. It
has been our institutional preference to use a central approach for arterial
cannulation to avoid the potential complications associated with peripheral
cannulation such as arterial dissection, embolism, retroperitoneal hema-
toma, and wound infection.
Cost outcomes. The primary end point of the analysis was total hos-
pital cost of the surgical admission. From the hospital perspective, we es-
timated total cost as all costs incurred from the time of operation to the time
of hospital discharge, including intraoperative and postoperative costs.
Hospital cost data were obtained from our institutional finance department
decision support system (Eclipsys Transition System Incorporated, At-
lanta, Ga), which provides audited clinical, financial, and operational
data.23 Of note, the reported cost data represent actual resource costs to
the hospital for services rendered rather than billed charges.
Total hospital cost was stratified into direct and indirect costs. Direct
costs represent costs associated with providing services or products to
the patient, such as laboratory tests, diagnostic imaging, medications, or
surgical procedures. Indirect costs represent hospital administrative ex-
penses not directly generated by patient care activities, such as facility
maintenance and administration. Total hospital cost was also stratified
into 13 standardized institutional billing categories, including blood
bank, cardiac imaging, cardiac catheterization laboratory, dialysis,1508 The Journal of Thoracic and Cardiovascular Suremergency room, laboratory, neurology, boarding and nursing, operating
room, pharmacy, radiology, rehabilitation, and respiratory care.
Clinical outcomes. Both short- and long-term clinical outcomes
were analyzed to assess the efficacy of MIMVS. Short-term outcomes in-
cluded cardiopulmonary bypass time, crossclamp time, hospital length of
stay, discharge location, andmajor in-hospital complications (ie, intubation
greater than 72 hours, renal failure, sepsis, reoperation for bleeding, stroke
less than 24 hours after surgery, stroke 24 hours or more after surgery, gas-
trointestinal bleeding, and transmural myocardial infarction). Long-term
outcomes included survival, freedom from reoperation, and the number
of medical or surgical readmissions occurring within 1 year of discharge.
Reasons for readmissions were categorized into the following: cardiac sur-
gery, pacemaker placement, percutaneous coronary intervention, arrhyth-
mia, pleural effusion, neurologic, or other causes.
Propensity matching. To account for differences in baseline char-
acteristics between groups, we used propensity score matching. A parsimo-
nious model of risk factors for selection to an MI versus ST approach was
created using 22 baseline patient characteristics and relevant operative vari-
ables includingmitral repair versus replacement, presence of a concomitant
procedure, and surgeon (Appendix 1). A stepwise logistic regression ap-
proach (backward, removeP>.20) was used for variable selection to create
the final model (Appendix 2). From this model, propensity scores were gen-
erated for each patient. Propensity scores were then nearest neighbor
matched 1:1 to create ST- and MI-matched pairs for analysis.
Statistical Analysis
Standard cost-effectiveness analyses are traditionally based on the dif-
ference in arithmetic mean cost.24 However, inasmuch as medical costs
are usually right skewed, as costs cannot be negative, we reported both
mean andmedian costs. Formean costs, we estimated associated bootstrap-
ped standard errors, using 1000 iterations, and applied the nonparametric
bootstrap t test, again using 1000 iterations, to compare costs between
groups.25 For median costs, results of the Wilcoxon rank sum test are re-
ported. To assess the independent effect of multiple baseline variables
(Appendix 1) and presence of complications on total hospital costs, we
used generalized linear models. Variable selection for generalized linear
models was performed via backward, stepwise regression (remove P>
.20); the traditional log-link function and gamma distribution we used as
per the modified Parks test.26 Owing to the log transformation, regression
coefficients are reported in exponentiated form to highlight the multiplica-
tive effect of a unit change in the independent variable on total hospital
cost.
For clinical data, continuous variables were reported as mean  stan-
dard error and were compared using the Student t test or Wilcoxon rank
sum test when noted. Categorical variables were reported as percentages
and compared using the c2 or Fisher’s exact test when appropriate.
Long-term survival and freedom from reoperation were assessed using
the Kaplan-Meier method and were compared using the log-rank test. Sur-
vival data were obtained from the Social Security Death Index and pro-
vided through December 14, 2009. Follow-up freedom from reoperation
data were obtained through June 1, 2010. All reported P values are
2-sided. All statistical analyses were performed using Stata 10 (Stata
Corp, College Station, Tex).RESULTS
Study Population
Between January 1, 2003, andDecember 31, 2008, 847pa-
tients underwent isolated MVS at our institution. Table 1
summarizes the baseline characteristics of the original study
population, with significant differences observed between
MI and ST groups across most variables. The final model
for propensity matching (Appendix 2) had an area undergery c December 2011
TABLE 1. Baseline characteristics of original study population
ST
(n ¼ 348)
MI
(n ¼ 499)
P
value
Age 63.2  0.82 58.8  0.61 <.0001
Body mass index 26.6  0.33 25.1  0.18 <.0001
Cerebrovascular accident 34 (9.8%) 21 (4.2%) .002
Chronic obstructive pulmonary
disease
27 (7.8%) 21 (4.2%) .034
Creatinine 1.31  0.08 0.97  0.02 <.0001
Current congestive heart failure 110 (31.6%) 70 (14.0%) <.001
Current smoker 13 (3.7%) 21 (4.2%) .859
Diabetes 41 (11.8%) 29 (5.8%) .002
Ejection fraction (%) 48.9  0.61 51.6  0.42 <.001
Gender (male) 192 (55.2%) 230 (46.1%) .009
Hepatic failure 1 (0.29%) 1 (0.20%) 1.0
History of endocarditis 15 (4.3%) 4 (0.80%) .098
History of ventricular arrhythmias 2 (0.57%) 2 (0.40%) 1.0
Immune system deficiency 22 (6.3%) 8 (1.6%) <.001
Intra-aortic balloon pump 4 (1.1%) 0 .028
Peripheral vascular disease 9 (2.6%) 4 (0.80%) .047
Previous myocardial infarction 26 (7.5%) 27 (5.4%) .249
Previous surgery 99 (28.5%) 30 (6.0%) <.001
Renal failure or dialysis 14 (4.0%) 2 (0.40%) <.001
Vasodilatory shock (preoperative) 4 (1.1%) 1 (0.20%) .654
ST, Sternotomy; MI, minimally invasive.
TABLE 2. Baseline characteristics of matched pairs
ST
(n ¼ 217)
MI
(n ¼ 217)
P
value
Age (y) 61.5  1.10 59.3  0.94 .117
Body mass index 25.7  0.38 25.6  0.30 .819
Cerebrovascular accident 19 (8.8%) 13 (6.0%) .359
Chronic obstructive
pulmonary disease
16 (7.4%) 10 (4.6%) .312
Creatinine (mg/dL) 1.21  0.10 1.02  0.05 .101
Current congestive heart
failure
51 (23.5%) 47 (21.7%) .731
Current smoker 5 (2.3%) 11 (5.1%) .202
Diabetes 17 (7.8%) 19 (8.8%) .862
Ejection fraction (%) 49.7  0.78 50.3  0.71 .576
Gender (male) 111 (51.2%) 111 (51.2%) 1.0
Hepatic failure 1 (0.46%) 0 1.0
History of endocarditis 5 (2.3%) 3 (1.4%) .724
History of ventricular
arrhythmias
1 (0.46%) 1 (0.46%) 1.0
Immune system deficiency 10 (4.6%) 7 (3.2%) .622
Intra-aortic balloon pump 3 (1.4%) 0 .248
Peripheral vascular disease 2 (0.92%) 2 (0.92%) 1.0
Previous myocardial
infarction
18 (8.3%) 18 (8.3%) 1.0
Previous surgery 26 (12.0%) 22 (10.1%) .647
Renal failure or dialysis 5 (2.3%) 2 (0.92%) .449
Vasodilatory shock
(preoperative)
2 (0.92%) 1 (0.46%) 1.0
ST, Sternotomy; MI, minimally invasive.
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demonstrating good model discrimination.
A total of 217 matched pairs were generated for a result-
ing sample size of 434 patients or 51.2% of the original
study population. Among the matched pairs, there were
no significant differences in major baseline characteristics
(Table 2).
Operative Characteristics
Among propensity matched MI patients, all mitral valve
operations were performed through a right minithoracot-
omy. There was no difference in the proportion of repairs
versus replacements (P¼ .768), with mitral valve repair be-
ing more common than replacement among both STand MI
groups. Also, there was no difference in mitral valve disease
(P ¼ .424) or mitral valve disease etiology (P ¼ .594)
(Table 3). In addition, there was no difference in the propor-
tion of concomitant procedures between groups (P¼ .141).
The cardiopulmonary bypass time was longer among MI
patients by 24.6  4.1 minutes (P<.0001), but the cross-
clamp time did not differ between groups (P ¼ .135).
Among MI patients, there were no conversions to a median
ST approach.
Cost Analysis
The MI approach was associated with a $9,054  $3,302
lower mean hospital cost of admission (ST: $50,060 
$2659; MI: $41,006  $1887; P ¼ .006). When median
cost was used, the reduction in total hospital cost wasThe Journal of Thoracic and Car$3595 (ST: $37,013; MI: $33,418; P ¼ .003). The MI ap-
proach was also associated with a $5993  $2008 lower
mean direct cost (ST: $29,273  $1610; MI: $23,279 
$1207; P ¼ .003), but there was no difference in mean indi-
rect cost between groups (ST: $20,787 $1320;MI: $17,727
 $993;P¼ .06) (Figure 1).Whenmedian cost was used, the
reduction in direct cost was $3270 (ST: $21,674; MI:
$18,404; P ¼ .001) and the reduction in indirect cost was
$1896 (ST: $15,185; MI: $13,289; P¼ .023). Among our in-
stitutional billing categories (Table 4), the lower cost of the
MI approach was primarily driven by a reduction in cost of
boarding and nursing (P¼ .001). Therewas a significant pos-
itive correlation between hospital length of stay and the cost
of boarding and nursing (0.923 [0.912-0.932]; P<.0001).
Lower costswere also observed amongMIpatients in the cat-
egories of cardiac imaging (P ¼ .004), laboratory tests
(P ¼ .005), and radiology (P ¼ .002).
In multivariable analysis, age (P ¼ .003), diabetes
(P ¼ .039), and previous surgery (P ¼ .001), as well as in-
tubation for more than 72 hours (P < .001) and sepsis
(P ¼ .03) were associated with higher total hospital costs
amongMI patients. Among ST patients, peripheral vascular
disease (P ¼ .036), intubation for more than 72 hours
(P< .001), and reoperation (P ¼ .005) were associated
with higher costs (Table 5).diovascular Surgery c Volume 142, Number 6 1509
TABLE 3. Operative characteristics of matched pairs
ST
(n ¼ 217)
MI
(n ¼ 217)
P
value
Mitral valve surgery type
Replacement 87 (40.1%) 83 (38.3%) .768
Repair 130 (59.9%) 134 (61.8%)
Mitral valve disease
Mitral regurgitation 185 (85.3%) 183 (84.3%) .424
Mitral stenosis 24 (11.1%) 30 (13.8%)
Mitral valve disease etiology
Degenerative 130 (59.9%) 128 (59.0%) .594
Anterior leaflet prolapse 28 (12.9%) 16 (7.4%)
Bileaflet prolapse 21 (9.7%) 33 (15.2%)
Posterior leaflet prolapse 81 (37.3%) 79 (36.4%)
Dilated cardiomyopathy 13 (6.0%) 10 (4.6%)
Endocarditis 19 (8.8%) 14 (6.5%)
Ischemic 9 (4.2%) 15 (6.9%)
Rheumatic 17 (7.8%) 25 (11.5%)
Calcific 22 (10.1%) 20 (9.2%)
Other 7 (3.2%) 5 (2.3%)
Concomitant procedures
Atrial septal defect repair 14 (6.5%) 18 (8.3%) .141
Atrial fibrillation ablation 50 (23.0%) 32 (14.7%)
Operative times (min)
CPB time 112.6  2.2 137.3  3.4 <.0001
Crossclamp time 75.8  1.6 80.7  2.8 .135
ST, Sternotomy; MI, minimally invasive; CPB, cardiopulmonary bypass.
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The mean length of stay was approximately 2 days
shorter among MI patients than ST patients (MI: 7.12 
0.36 days; ST: 9.19  0.52 days; P ¼ .001). The difference
in median lengths of stay for MI and ST patients was also
statistically significant (MI: 6 days; ST: 7 days;
P ¼ .0001). In terms of postoperative complications, there
were no significant differences in gastrointestinal bleedingFIGURE 1. Total and stratified hospital costs with bootstrapped standard
error estimates. ST, Sternotomy;MI,minimally invasive. *Statistically sig-
nificant difference between groups.
1510 The Journal of Thoracic and Cardiovascular Sur(P¼ 1.0), renal failure (P¼ .284), reoperation for bleeding
(P ¼ .544), sepsis (P ¼ 1.0), stroke less than 24 hours after
surgery (P ¼ .623), stroke 24 hours or more after surgery
(P ¼ .685), or transmural myocardial infarction
(P ¼ 1.0). There was, however, a greater proportion of pa-
tients in the ST group who required intubation for more than
72 hours: ST: 8.3% (n ¼ 18), MI: 2.8% (n ¼ 6): P ¼ .019.
The mean duration of survival follow-up was 3.2  1.6
years. There was no difference in survival at 30 days
(P ¼ .503) or 1-year (P ¼ .827) between groups. There
was also no significant difference in long-term survival
(P ¼ .334).
There was a significant difference in the distribution of
discharge locations between MI and ST patients
(P ¼ .018) (Table 6). A higher proportion of MI patients
(66.8%, n ¼ 135) were discharged home with no nursing
services compared with ST (54.4%, n ¼ 111), whereas
a higher proportion of ST patients were discharged home
with a nursing aide (30.9%, n ¼ 63) compared with MI
(25.7%, n ¼ 52). In addition, a higher proportion of ST pa-
tients (14.7%, n¼ 30) were discharged to rehabilitation fa-
cilities when compared with MI patients (7.5%, n ¼ 15).
Hospital readmissions within 1 year of surgery were also
studied between groups, and there were a higher proportion
of readmissions among ST patients (ST: 13.7%, n ¼ 28;
MI: 6.8%, n¼ 14; P¼ .023). In both groups, the most com-
mon cause for readmission was arrhythmias managed med-
ically (Table 6). With regard to freedom from reoperation,
there was no significant difference between groups
(P ¼ .574) (Figure 2). The average duration of follow-up
was 4.5  1.7 years.
DISCUSSION
Over the past 2 years, there has been a growth of interest
in the economic evaluation of new surgical technologies
and techniques, coinciding with increased national attention
to comparative effectiveness research.27,28 While early
studies by Chitwood,7,19 Cohn,5 Cosgrove,20 and their asso-
ciates in the 1990s reported 7% to 34% cost savings asso-
ciated with MIMVS, no studies in the past decade have
specifically compared costs between MI and STapproaches
as a primary end point.
In our analysis, patients undergoingMIMVS had a $9054
lower mean total cost of admission resulting in cost savings
of 18% compared with the ST approach. In addition, we
demonstrate that the difference in hospital cost between
groups was largely driven by differences in direct rather
than indirect costs. These results support the generalizabil-
ity of our findings as direct costs involve costs related to pa-
tient care, whereas indirect costs represent costs attributable
to hospital maintenance and utilities, which may vary from
region to region.
The hypothesis that MIMVS could be cost saving has
been driven largely by the observation that patientsgery c December 2011
TABLE 4. Total hospital costs stratified by billing category
Cost category
Mean cost Median cost
ST (n ¼ 217) MI (n ¼ 217) P value ST (n ¼ 217) MI (n ¼ 217) P value
Blood bank $1426  131 $1605  238 .151 $898 $585 .262
Cardiac imaging $297  27 $201  19 .004 $188 $56 .002
Cardiac catheterization $4344  218 $4500  179 .588 $4,165 $4343 .130
Dialysis $5313  4649 $556  500 .487 $1,361 $556 .564
Emergency room $1452  214 $1032  296 .234 $1,756 $324 .551
Laboratory tests $1953  159 $1404  108 .004 $1,282 $1006 <.001
Neurology $1919  1451 $407  301 .309 $127 $152 .952
Boarding and nursing $21,950  1565 $15,798  1027 .001 $13,367 $11,157 <.001
Operating room $15,905  438 $15,984  322 .888 $14,699 $14,874 .356
Pharmacy $3157  413 $2668  275 .330 $1,859 $1569 .064
Radiology $1770  236 $954  97 .002 $733 $608 .004
Rehabilitation $853  98 $723  85 .344 $591 $464 .005
Respiratory care $1632  329 $1349  215 .466 $578 $661 .464
ST, Sternotomy; MI, minimally invasive.
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In a recent meta-analysis by Modi and associates,29 8 of 14
studies on MIMVS reported a shorter hospital stay when
compared to the ST approach.30 We have previously re-
ported a shorter length of stay among MIMVS patients.18
In this cohort, we estimated the difference was approxi-
mately 2 days on average. Notably, among our institutional
billing categories we found significant differences in costs
associated with boarding and nursing, laboratory tests, radi-
ology, and cardiac imaging. As expected, there was a signif-
icant, positive correlation between length of stay and costs
of boarding and nursing. Individuals in a hospital for fewer
days will incur less boarding and nursing costs, and will also
likely have lower costs associated with routine activities
such as daily laboratory and imaging studies. In ourTABLE 5. Baseline patient characteristics and postoperative
complications associated with total hospital costs significant in
multivariable regression
Exp b
coefficient 95% CI
P
value
Baseline patient characteristic
ST
Peripheral vascular disease 2.41 1.06-5.45 .036
MI
Age 1.01 1.00-1.02 .003
Diabetes 1.39 1.02-1.90 .039
Previous surgery 1.65 1.24-2.19 .001
Complications
ST
Intubation>72 h 3.06 2.25-4.16 <.001
Reoperation 2.02 1.24-3.28 .005
MI
Intubation>72 h 2.64 1.64-4.26 <.001
Sepsis 3.45 1.13-6.56 .03
CI, Confidence interval; ST, sternotomy; MI, minimally invasive.
The Journal of Thoracic and Carmultivariable analysis, intubation for more than 72 hours
was a significant independent predictor of total hospital
cost shared by both MI and ST groups. MI patients had
a 5.5% lower rate of this complication; however, the overall
prevalence of this complication in the series was low. Thus,
although our results demonstrate that the majority of cost
savings associated with MIMVS occurred in the category
of boarding and nursing, which results from a shorter length
of stay, further research is necessary to determine the exact
cause of the shorter hospitalization. In addition to shorter
intubation times, other factors may include decreased post-
operative pain and improved postoperative physical
rehabilitation.
Also, it must be noted that although MI patients had
a shorter length of stay than ST patients, the mean lengths
of stay for MI and ST groups were 7.1 and 9.2 days, respec-
tively. There is likely significant variability from one hospi-
tal to the next with respect to hospital stay. For example,
Suri and associates30 reported lengths of stay of 6.95 days
for port access patients and 6.19 days among ST patients
who received mitral valve repairs. A recent executive sum-
mary of The Society of Thoracic Surgeons Adult Cardiac
Surgery Database reported a mean length of stay of 10.5
days for all mitral valve replacements and 7 days for all mi-
tral valve repairs performed in 2009.31 Gammie and associ-
ates32 analyzed all less invasive mitral valve operations in
The Society of Thoracic Surgeons Database from 2004 to
2008 and reported a 6.9-day risk-adjusted mean hospital
stay for the less invasive group.31 Thus, hospital stays
vary from one center to the next, and those reported in
our analysis for MI and ST patients, which included both re-
pairs and replacements, may be slightly higher than those
observed in other centers. This variability may be explained
by the fact that patients in our analysis had numerous co-
morbidities. For example, among propensity matched
MIMVS patients, 22% had congestive heart failure, 8.8%diovascular Surgery c Volume 142, Number 6 1511
TABLE 6. In-hospital complications, short-term survival, discharge
location, and readmissions
ST
(n ¼ 217)
MI
(n ¼ 217)
P
value
Complications
Gastrointestinal bleed 1 (0.46%) 1 (0.46%) 1.0
Intubation>72 h 18 (8.3%) 6 (2.8%) .019
Renal failure 6 (2.8%) 2 (0.92%) .284
Reoperation for bleeding 7 (3.2%) 4 (1.8%) .544
Sepsis 2 (0.92%) 3 (1.4%) 1.0
Stroke (<24 h) 3 (1.4%) 1 (0.46%) .623
Stroke ( 24 h) 4 (1.8%) 2 (0.92%) .685
Transmural myocardial
infarction
0 0 1.0
Mortality
Thirty-day mortality 3 (1.4%) 6 (2.8%) .503
One-year mortality 12 (5.5%) 10 (4.6%) .827
Discharge location (n ¼ 204) (n ¼ 202)
Home with no nursing
services
111 (54.4%) 135 (66.8%) .018
Home with nursing aide 63 (30.9%) 52 (25.7%)
Skilled nursing facility 16 (7.8%) 5 (2.5%)
Short-term, acute
rehabilitation
2 (0.98%) 0
Other rehabilitation facility 12 (5.9%) 10 (5.0%)
Readmission (n ¼ 205) (n ¼ 207)
No readmissions within 1 y 177 (86.3%) 193 (93.2%) .023
 1 readmission within 1 y 28 (13.7%) 14 (6.8%)
Cardiac surgery 3 (10.7%) 2 (14.3%)
Pacemaker insertion 4 (14.3%) 3 (21.4%)
PCI 4 (14.3%) 1 (7.1%)
Arrhythmia 6 (21.4%) 4 (28.6%)
Chest pain or CHF 6 (21.4%) 1 (7.1%)
CVA/TIA 2 (7.1%) 1 (7.1%)
Pleural effusion 3 (10.7%) 2 (14.3%)
Note that readmission subcategory percentages are based on the number of 1 read-
mits. PCI, Percutaneous coronary intervention; CHF, congestive heart failure; CVA,
cerebrovascular accident; TIA, transient ischemic attack.
FIGURE 2. Freedom from mitral valve reoperation. ST, Sternotomy; MI,
minimally invasive.
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and 6% had a previous cerebrovascular accident. In addi-
tion to patient risk, hospital logistical factors such as bed
availability and rehabilitation center transfer rates may re-
sult in hospital stay variability from one center to the
next. Importantly, however, baseline risk did not differ
among propensity matched groups and it is unlikely that lo-
gistical factors differentially affected one group versus the
other in our analysis.
One of the early concerns withMIMVSwas that a smaller
incision would result in prolonged operative times and po-
tentially increased resource use in the operating room. In
our analysis, MIMVS was associated with an equivalent
crossclamp time compared with ST and a mean bypass
time that was longer by only 25 minutes. Despite this
slightly longer bypass time, there was no significant differ-
ence in operating room costs between groups.1512 The Journal of Thoracic and Cardiovascular SurTraditional cost-effective analyses generally report the
incremental cost-effectiveness ratio between 2 treatments
as the difference in average cost divided by the difference
in average effectiveness, often in the form of quality-
adjusted life years. Inasmuch as our study was retrospec-
tive, no data on postoperative quality-adjusted life years
was available. Furthermore, a literature search revealed no
contemporary studies that have prospectively compared
quality of life between MI and ST MVS. In the absence
of such data, effectiveness could be analyzed from the per-
spective of valve integrity and freedom from reoperation.
We found no difference in freedom from reoperation be-
tween groups, and these findings are consistent with other
studies reporting freedom from reoperation rates ranging
from 99.3% at 3.2 years to 91% at 4 years for MIMVS.30
Although long-term postoperative echocardiographic data
were not available in our retrospective analysis, a recent
study by Svensson and coworkers9 demonstrated no differ-
ence in the proportion of patients with mitral regurgitation
grade 3þ or 4þ at 1 and 5 years when compared with the
STapproach.9 Moreover, in our analysis therewas no differ-
ence in morbidity, mortality, or long-term survival between
groups. Therefore, on the basis of its lower cost and equiv-
alent efficacy and safety relative to ST, our results suggest
that MIMVS is cost-saving and cost-effective.
The cost savings associated with MIMVS could poten-
tially be an underestimate in our analysis because we only
included costs associated with the surgical admission. Fur-
ther cost savings associated with MIMVS could be realized
if the time horizon of our economic analysis was expanded
to 1 year. More patients undergoing MIMVS were dis-
charged home with no nursing services and fewer required
transfer to rehabilitation facilities on discharge, represent-
ing significant cost savings. In addition, at 1 year the rate
of hospital readmission for MI patients was half that of
ST patients, which represents significant additional costgery c December 2011
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Dsavings. Although the reasons for the observed lower read-
mission rate are an area of ongoing research, it is possible
that improved functional status, as suggested by lower
nursing and rehabilitation services, may facilitate overall
recovery and prevent deconditioning associated with post-
operative complications.
Limitations
There are several limitations to our analysis. First, our
study is retrospective and subject to multiple potential
biases. At our institution, the decision to pursue an MI ap-
proach involves an overall assessment of the feasibility
and safety of such an approach based on the patient’s preop-
erative risk. MIMVS is particularly challenging, for exam-
ple, in patients with previous cardiac surgery, chronic
obstructive pulmonary disease, and elevated body mass in-
dex, and this is reflected in the differences in baseline char-
acteristics among unmatched pairs in Table 1. Although the
C-statistic of our propensity scoremodel demonstrated good
model discrimination, selection bias cannot be completely
eliminated through propensity matching. Also, it is possible
that while 22 variables were considered in the propensity
model, other risk factors may influence the selection to an
MI versus an ST approach. Second, data on readmission
and reoperation reflect only hospital readmissions that oc-
curred at our institution. Therefore, a fraction of these events
that occurred outside our hospital would not be included in
the analysis. Nevertheless, it is unlikely that the rates of
these occurrences at other institutions would have been dif-
ferent between groups. Last, our results do not take into ac-
count the potential effect of learning curves on clinical
outcomes and the possibility that cost savings associated
withMIMVSmay not be realized early in the learning curve,
or that overall cost savings associated withMIMVSmay not
be significant in magnitude at low-volume MVS centers.
CONCLUSIONS
MIMVS is a cost-effective and cost-saving strategy for
mitral valve repair and replacement compared with the tra-
ditional STapproach with lower cost driven largely by a de-
creased length of stay. However, MIMVS demonstrated
comparable efficacy across a range of efficacy measures
such as freedom from reoperation, long-term survival, and
in-hospital morbidity. As clinical trials emerge on the use
of transcatheter mitral valve technologies and quality of
life and cost become increasingly integrated into study
end points, MIMVS may represent the standard on which
to compare such emerging technologies.
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into logistic regression model to predict selection to MI versus ST
approach
Variable
Odds ratio
MI:ST 95% CI
P
value
Patient baseline
Age 0.974 0.965-0.984 <.001
BMI 0.943 0.917-0.971 <.001
CVA 0.406 0.231-0.712 .002
COPD 0.522 0.290-0.940 .030
Creatinine 0.522 0.290-0.940 .030
Current CHF 0.353 0.252-0.495 <.001
Current smoker 1.13 0.559-2.29 .730
Diabetes 0.462 0.281-0.759 .002
Ejection fraction 1.02 1.01-1.04 <.001
Gender (male) 0.694 0.528-0.915 .009
Hepatic failure 0.697 0.043-11.18 .799
History of endocarditis 0.375 0.124-1.14 .084
History of ventricular arrhythmias 0.696 0.098-4.97 .718
Immune system deficiency 0.241 0.106-0.549 .001
Peripheral vascular disease 0.304 0.093-0.996 .049
Previous myocardial infarction 0.708 0.406-1.24 .225
Previous cardiac surgery 0.161 0.104-0.249 <.001
Renal failure or dialysis 0.096 0.022-0.425 .002
Vasodilatory shock preoperative) 0.357 0.040-3.21 .357
Operative
Repair versus replacement 6.37 4.68-8.66 <.001
Secondary minor procedure 1.02 0.983-1.05 .353
Surgeon 0.917 0.850-0.988 .023
MI,Minimally invasive; ST, sternotomy; CI, confidence interval; BMI, body mass in-
dex; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease;
CHF, congestive heart failure.
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1401-8.APPENDIX 2. Final regression model used to generate propensity
scores
Risk factor
Odds ratio
MI:ST 95% CI
P
value
Age 0.981 0.970-0.993 .002
BMI 0.940 0.909-0.972 <.001
Current CHF 0.565 0.372-0.856 .007
Ejection fraction 1.02 1.01-1.04 .019
Immune system deficiency 0.367 0.146-0.922 .033
Previous cardiac surgery 0.243 0.142-0.415 <.001
Previous myocardial infarction 2.12 1.04-4.33 .002
Repair versus replacement 4.65 3.26-6.62 <.001
Renal failure or dialysis 0.159 0.031-0.840 .007
Secondary minor procedure 0.962 0.921-0.997 .036
MI,Minimally invasive; ST, sternotomy; CI, confidence interval; BMI, body mass in-
dex; CHF, congestive heart failure.
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